Innovative drug R&D in China.
作者信息
Qi Jingzong, Wang Qingli, Yu Zhenhang, Chen Xin, Wang Fengshan
出版信息
Nat Rev Drug Discov. 2011 May;10(5):333-4. doi: 10.1038/nrd3435.
DOI:10.1038/nrd3435
PMID:21532556
Abstract
摘要
相似文献
1
Innovative drug R&D in China.
Nat Rev Drug Discov. 2011 May;10(5):333-4. doi: 10.1038/nrd3435.
2
Pharmaceutical sciences in 2020.
Nat Rev Drug Discov. 2010 Feb;9(2):99-100. doi: 10.1038/nrd3087.
3
A status report on neuroscience research, without grade inflation.
Ann Neurol. 2006 Dec;60(6):A9-11. doi: 10.1002/ana.21054.
4
Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.
Drug Discov Today. 2007 Apr;12(7-8):289-94. doi: 10.1016/j.drudis.2007.02.004. Epub 2007 Feb 20.
5
[Partnership between drug industry and the university--innovation, proof of efficacy, drug safety].
Z Gastroenterol. 1999 Jul;Suppl 2:12-8.
6
BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
IDrugs. 2006 Jun;9(6):386-9.
7
Science, medicine and... the markets.
J Hepatol. 2006 Sep;45(3):341-2. doi: 10.1016/j.jhep.2006.06.008. Epub 2006 Jul 7.
8
Clinical research: outlook from industry.
Clin Perform Qual Health Care. 1996 Apr-Jun;4(2):113-4.
9
Overcoming the challenges in the pharma/biotech industry.
Drug News Perspect. 2007 Jan-Feb;20(1):57-68.
10
An audience with...Marc Cluzel.
Nat Rev Drug Discov. 2010 Jan;9(1):14. doi: 10.1038/nrd3090.
引用本文的文献
1
Obstacles and opportunities in Chinese pharmaceutical innovation.
Global Health. 2017 Mar 24;13(1):21. doi: 10.1186/s12992-017-0244-6.
2
A proposed definition of rare diseases for China: from the perspective of return on investment in new orphan drugs.
Orphanet J Rare Dis. 2015 Mar 7;10:28. doi: 10.1186/s13023-015-0241-x.
3
Life sciences venture capital in emerging markets.
Nat Biotechnol. 2013 Mar;31(3):195-201. doi: 10.1038/nbt.2529.
Zotero 插件